Z

Zoetis Services

Develops, manufactures, and sells animal vaccines

Freight Audit Associate

Full-TimeDeadline 10/22/26
No salary listed
Junior
Bachelor's
Hyderabad, Telangana, India
RemoteRegular working hours are 11:00 AM to 8:00 PM IST; occasional greater overlap with the Eastern Time zone may be required.
AccountingAccounts Payable/Receivable

About the job

Requirements
  • A bachelor's degree in Finance, Business, Information Technology, or a related field.
  • At least 2 years of experience in audit or accounts payable using SAP or other financial tools.
  • Analytical and problem-solving skills.
  • Good experience with Excel and numerical data.
  • Experience working with cross-functional teams and the ability to work in a matrix organization across global functions and regions.
  • Ability to collaborate with freight forwarders across APACA, EME, the United States, and CLAR through recurring meetings.
  • Ability to build strong internal and external partnerships to improve end-to-end performance.
  • Ability to ensure timely and accurate carrier setup and manage payment and dispute resolution end to end.
  • Ability to maintain Zoetis-approved carrier rate tables.
  • Ability to audit freight invoices against approved rates and required coding, including business entity, cost center, and general ledger account.
  • Ability to request credit notes or invoice resubmissions for discrepancies and provide reporting and root-cause insights.
  • Ability to use SAP Transportation Management, BN4L, and Business Technology Platform to validate invoices, resolve disputes, and drive corrective and preventive actions.
  • Ability to prepare key performance indicators on invoice status and spend.
  • Ability to apply critical thinking and problem-solving to make sound decisions and resolve issues efficiently.
  • Ability to communicate clearly and effectively with stakeholders.
  • Ability to establish process governance and identify opportunities to automate process steps through technology and data.
  • Ability to meet the physical requirements of the role, including lifting up to 22 kg, bending, climbing, and grabbing.
Responsibilities
  • Review system disputes across categories, prepare strategic solutions, and align with logistics service providers in meetings.
  • Hold recurring daily or weekly meetings with logistics service providers, the supply chain team, and the transportation team to resolve disputes.
  • Maintain and transform data to meet business requirements, address data submission failures, and develop solutions.
  • Collaborate with the transportation team to enhance the SAP solution and continuously improve processes.
  • Monitor global logistics trends, including logistics rates, fuel prices, and surcharges.
  • Train and transfer knowledge to team members, users, and stakeholders as required.
  • Interact with global transportation, Finance, and Zoetis Financial Services teams to resolve issues promptly.
  • Work with freight forwarders and maintain business relationships.
  • Interact with internal transportation teams to improve and resolve freight-audit systems.
  • Maintain expert knowledge of freight-audit requirements and the internal and external business environment, and complete required training.
  • Manage carrier payment and dispute resolution processes end to end.
  • Maintain carrier rate tables and audit freight invoices against approved rates and coding.
  • Request credit notes or invoice resubmissions, and provide reporting and root-cause insights to prevent recurrence.
  • Prepare key performance indicators on invoice status and spend.
  • Perform general pharmacovigilance duties.
Desired Qualifications
  • Experience in logistics, fast-moving consumer goods, and supply chain.
  • Previous experience in a freight-audit role.

About the company

Z

Zoetis Services

View
Website

Zoetis creates medicines and vaccines to protect the health of companion animals and livestock. Its products include vaccines, anti-infectives, parasiticides, dermatology and other therapeutics, medicated feed additives, and diagnostics, sold through veterinarians, livestock producers, and pet owners. The company reaches customers in more than 100 countries and relies on big R&D and a global marketing network to bring new solutions to market. Its goal is to improve animal health worldwide by delivering science-based products and services that help care for animals and prevent disease.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parsippany-Troy Hills, New Jersey

Founded

1952

Get referred to Zoetis Services

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA granted Simparica Trio EUA on August 13, 2026 for screwworm in dogs.
  • Livestock revenue grew double digits in 2026, led by cattle, poultry, and fish.
  • Lenivia and Portela launches in Canada and Europe expand osteoarthritis pain coverage.

What critics are saying

  • U.S. companion-animal revenue fell 7% in Q2 2026 as clinic visits weakened.
  • Elanco and Merck are squeezing Apoquel and Simparica with promotions through 2027.
  • If dermatology share keeps eroding, Zoetis becomes a slower livestock-and-diagnostics utility.

What makes Zoetis Services unique

  • Zoetis dominates veterinary channels with a broad companion-animal and livestock portfolio.
  • Its pipeline spans renal disease, oncology, cardiology, and dermatology, unlike commodity peers.
  • Global reach across 100-plus countries gives Zoetis pricing power and distribution leverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

13%

1 year growth

15%

2 year growth

15%
Yahoo Finance
Oct 20th, 2026
FDA approves Zoetis' Convenia RTU, a single-injection antibiotic for dogs of all sizes

Zoetis Inc. said the US Food and Drug Administration (FDA) has approved Convenia RTU for Dogs, a single injection that treats susceptible bacterial skin infections in dogs for up to 14 days. A veterinary professional gives the shot, which spares owners from daily oral antibiotics and helps ensure the full dose is given. The formula is more concentrated, so it delivers the same dose in a smaller volume, making single-injection treatment more practical for medium and large dogs. The product is bioequivalent to Convenia, which the FDA approved in 2008. In a study, 86% of dogs needed just one injection of cefovecin to clear their infection. Zoetis expects the product to reach veterinarians in the first quarter of 2027.

Insider Monkey
Oct 16th, 2026
Zoetis' valuation has fallen sharply, but has the market overreacted?

Zoetis' valuation has fallen sharply, but has the market overreacted? Zoetis has lost more than half its value over the past year as weaker U.S. companion-animal demand pressured results, but its roughly 12x forward P/E leaves investors weighing a much cheaper valuation against a meaningful slowdown in the business. Published October 16, 2026 at 11:29 am EDT The investment case for Zoetis Inc. (NYSE:ZTS) has changed significantly since declining demand in its U.S. companion-animal business has put pressure on earnings forecasts and affected the price of its shares. As a company in the animal health sector, Zoetis produces medicines, vaccines, and diagnostic products for both pets and livestock, and the wide range of its product offerings provides long-term growth possibilities. However, because management has revised its 2026 earnings forecast, investors now have to decide whether the stock's lower forward P/E indicates an attractive place to buy the shares or suggests a more conservative view of future growth. The collapse in the share price has also changed Zoetis' valuation considerably. The stock is down over 45% in the past 12 months. Yahoo Finance currently reports a forward P/E of approximately 12.0x, compared with 21.69x as of September 30, 2025, which makes the stock look substantially cheaper than it did a year ago. However, the lower multiple is not occurring in isolation, as the company has also materially reduced its 2026 earnings expectations. Zoetis has dramatically underperformed the market, but other stocks in the sector haven't. We made a list of the best healthcare stocks to buy according to hedge funds. Check out the complete list here to make an informed decision. The earnings outlook has weakened. We meticulously crafted a list of the 7 Best Pharma Stocks to Invest In Now. Access the complete list here. Zoetis Inc. (NYSE:ZTS) reported second-quarter 2026 revenue of $2.5 billion, essentially flat from a year earlier, while adjusted diluted EPS was $1.87. On an organic operational basis, however, revenue declined 1% and adjusted net income declined 2%. The company's full-year outlook shows why the market has become more cautious. Zoetis now expects 2026 revenue of $9.12 billion to $9.32 billion, corresponding to organic operational revenue growth of (3)% to (1)%. Adjusted diluted EPS is expected at $6.15 to $6.25, and the company also revised its full-year 2026 adjusted net income guidance to organic operational growth of (9)% to (5)%. That is a significant change from the company's May outlook, when Zoetis was expecting revenue of $9.68 billion to $9.96 billion and adjusted EPS of $6.85 to $7.00. But before we dive further into the investment story, take a look at our recently published article on Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth? for more insight. Companion-Animal weakness is the main problem. The pressure is concentrated in one of Zoetis' most important markets. U.S. revenue declined 7% in the second quarter, with companion-animal product sales falling 11%. Zoetis said lower clinic visits, pet-owner price sensitivity, and heightened competition affected several products, while generic competition also weighed on Cerenia and Convenia. There are, however, areas of resilience. U.S. sales of livestock products increased 23%, supported by cattle and poultry, while international revenue rose 8% on a reported basis and 6% organically. International companion-animal product sales increased 5% organically. These trends are significant for investors to note to ensure that Zoetis is not essentially facing a company-wide collapse. Instead, the problem is that weakness in the U.S. companion-animal business is offsetting growth elsewhere. We talked about ZTS's bear case and U.S. business in detail in our insightful article on Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?. Read the full analysis here. The pipeline could help, but growth will take time. Zoetis still has significant opportunities to rebuild growth. The company says its pipeline contains more than 12 potential blockbuster candidates, including programs targeting chronic kidney disease, oncology, cardiology, anxiety and obesity. The company is also expanding its diagnostics business and completed the acquisition of VitalRADS, a veterinary teleradiology platform, in July. Zoetis said the acquisition is intended to expand its Global Diagnostics offering into veterinary imaging interpretation. Its response to the New World screwworm threat provides another example of its existing portfolio becoming strategically relevant. Dectomax-CA1 received FDA conditional approval for prevention and treatment of screwworm myiasis in beef cattle, while Zoetis also received emergency-use authorization covering several other animal species. Does 12x earnings make the stock attractive? At roughly 12x forward earnings, Zoetis Inc. (NYSE:ZTS) is considerably cheaper than it was a year ago. But the market has a reasonable explanation for that discount, which is that management currently expects organic revenue and adjusted earnings to decline in 2026. The investment case therefore depends on whether the current weakness is temporary or represents a more lasting deterioration in the companion-animal market. If clinic visits, pet-owner spending, and demand for Zoetis' products recover, the current valuation could leave room for earnings growth to regain momentum. If those pressures persist, however, the stock's low multiple may be justified. At this point, 12x forward earnings looks materially less demanding, but not automatically cheap. The valuation has changed dramatically, and the next question is whether Zoetis can stabilize the business enough to make that lower multiple meaningful.

Morning Ag Clips
Oct 15th, 2026
2026 USPOULTRY Live Production, Welfare & Biosecurity Seminar highlights technology, bird Welfare and Biosecurity.

2026 USPOULTRY Live Production, Welfare & Biosecurity Seminar highlights technology, bird Welfare and Biosecurity. Erin Patrick, supervisory wildlife biologist with USDA APHIS, discussed efforts to reduce the risk of HPAI introductions through improved wildlife biosecurity. PUBLISHED ON October 15, 2026 Dr. Eric Shepherd, poultry veterinarian at Zoetis, speaking at the 2026 Live Production, Welfare and Biosecurity Seminar in Nashville, Tenn. (Photo provided) TUCKER, Ga. - The 2026 USPOULTRY Live Production, Welfare & Biosecurity Seminar brought together industry professionals to explore challenges and opportunities impacting poultry production. The program provided attendees with insight into wildlife biosecurity and highly pathogenic avian influenza (HPAI) prevention, precision farming technologies, emerging poultry disease trends, and evolving approaches to animal welfare and layer housing. Erin Patrick, supervisory wildlife biologist with the U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS), discussed efforts to reduce the risk of HPAI introductions through improved wildlife biosecurity. She discussed the APHIS Wildlife Services' Wildlife Biosecurity Assessment program that helps producers identify wildlife activity and farm-specific hazards and develop mitigation strategies. Patrick explained that waterfowl can carry HPAI during migration, while wildlife found around farms may provide a link between infected waterfowl and commercial poultry. She emphasized that wildlife biosecurity is premise-specific and can provide an "ounce of prevention" against HPAI introductions. During his presentation on Precision Farming Technology, Casey Middlebrooks, data scientist at Fieldale Farms Corporation, observed how sensors monitoring feed and water consumption, temperature, and humidity can help identify potential health, welfare or equipment concerns between routine farm visits. He remarked that the technology can provide continued visibility when onsite access is restricted. Middlebrooks also emphasized that these technologies are intended to complement, not replace, stockmanship and human decision-making. Dr. Eric Shepherd, poultry veterinarian at Zoetis, provided a poultry disease update, noting that HPAI will likely remain a seasonal challenge, with potential year-round activity in parts of the Upper Midwest. He said avian metapneumovirus may lessen as vaccination strategies improve, while infectious laryngotracheitis will likely continue to occur throughout the year. Shepherd also discussed uncertainty surrounding Mycoplasma synoviae and cautioned that reductions in vaccine spending could lead to increased disease challenges in the field. As part of his presentation on Outcome-Based Animal Welfare and Key Welfare Indicators, Dr. Darrin Karcher, poultry Extension specialist at Penn State University, reviewed alternative housing systems for commercial layers. Karcher talked about the shift toward cage-free housing and trade-offs among housing systems related to bird health and behavior, stress, egg cleanliness, space and the worker environment. He also highlighted ongoing USDA-funded research using agent-based modeling to better understand how hens interact with cage-free housing systems.

MarketScreener
Oct 13th, 2026
Zoetis Inc. announces appointment of Iris Knobloch as director, effective December 1, 2026.

Zoetis Inc. announces appointment of Iris Knobloch as director, effective December 1, 2026. Published on 10/13/2026 at 10:20 am EDT S&P Capital IQ Zoetis Inc. announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. Ms. Knobloch has been appointed to serve on the Board?s Corporate Governance Committee. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of Deezer S.A., Lazard Inc. and Vail Resorts Inc., and has built a track record of effective governance across complex, global organizations. Ms. Knobloch has served as President of the Festival de Cannes, a leading international film festival, since July 2022. From 2021 to July 2022, she served as Chair and CEO of I2PO S.A. prior to its business combination with Deezer S.A., a global music streaming platform, when she transitioned to Deezer's Board of Directors where she has served as its Chair of the Board since January 2023. Ms. Knobloch previously held senior executive positions at WarnerMedia and its predecessor companies, global media and entertainment businesses, including as President of WarnerMedia in France, Germany, the Benelux, Austria and Switzerland. Earlier in her career, Ms. Knobloch was responsible for Time Warner's International Relations and Strategic Policy for Europe and practiced law with O'Melveny & Meyers and Noerr, Stiefenhofer & Lutz. Ms. Knobloch brings extensive public company board experience across global consumer, financial services, media and digital businesses. She has served as a director of Lazard Inc., a global financial advisory and asset management firm, since April 2018, and Vail Resorts Inc., a global hospitality business, since February 2024. Ms. Knobloch has previously served on the boards of Accor S.A., LVMH Moet Hennessy Louis Vuitton, SE, Central European Media Enterprises N.V. and Axel Springer SE. She is also a Governor of the American Hospital of Paris and a member of the Supervisory Board of the BMW Foundation Herbert Quandt, a nonprofit foundation dedicated to advancing responsible leadership and contributing to peaceful, just and sustainable societies. She holds a Doctorate in Law from Ludwig-Maximilians-Universitaet and a Master of Laws from New York University. With Ms. Knobloch's appointment, Zoetis will increase the size of its Board of Directors from 12 to 13 members, effective as of December 1, 2026. (C) S&P Capital IQ - 2026

Yahoo Finance
Oct 13th, 2026
Zoetis appoints Cannes Film Festival president Iris Knobloch to board, expanding it to 13 members

Zoetis has appointed Iris Knobloch to its board of directors, effective December 1, 2026. The appointment raises the animal health company's board from 12 to 13 members. Knobloch has been president of the Festival de Cannes since July 2022. She chairs the board of music streaming platform Deezer and also sits on the boards of Lazard and Vail Resorts. She previously held senior roles at WarnerMedia. Chief executive officer Kristin Peck said Knobloch's experience in consumer strategy, digital transformation, and regulatory environments will help as Zoetis explores new ways to connect with pet owners.